The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions
- 24 June 2026
- journal article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 290, 298-305
Abstract
No abstract availableKeywords
Funding Information
- Cleveland Eye Bank Foundation (Grant)
- National Institutes of Health (UL1TR002548)
- Research to Prevent Blindness (Challenge Grant)
This publication has 27 references indexed in Scilit:
- Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysisJournal of Stroke and Cerebrovascular Diseases, 2024
- Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life settingActa Diabetologica, 2021
- Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular OutcomesThe American Journal of Cardiology, 2019
- Elevated Lipoprotein(a) and Risk of Ischemic StrokeJACC, 2019
- Improved endothelial function after short-term therapy with evolocumabJournal of Clinical Lipidology, 2018
- Effect of oral niacin on central retinal vein occlusionGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusionGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusionAtherosclerosis, 2010
- Retinal Vein Occlusion and Traditional Risk Factors for AtherosclerosisArchives of Ophthalmology (1950), 2008
- Risk Factors for Central Retinal Vein OcclusionArchives of Ophthalmology (1950), 1996